带状疱疹患者病情评分与血浆S100β和NSE水平的相关性分析

Analysis of the Correlation between the Severity Score and the Level of Plasma S100β and NSE in Patients with Herpes Zoster

目的探讨带状疱疹(herpes zoster,HZ)患者急性期和恢复期病情评分与其血浆S100β蛋白和NSE水平的相关性及临床意义。方法收集2014年5月-10月在本科住院的50例急性期HZ患者,于入院时和出院时按HZ病情评分标准进行病情评分,采用ELISA法检测其血浆S100β蛋白和神经元特异性烯醇化酶(neuron specific enolase,NSE)含量,并与同期在本院体检的20名健康志愿者进行对照。比较HZ患者病情严重程度与血浆S100β,NSE的相关性。随访出院后1个月带状疱疹后遗神经痛(postherpetic neuralgia,PHN)发生情况。结果 HZ组治疗后病情评分明显低于其治疗前(P<0.001)。HZ组治疗前后血浆S100β,NSE均较正常对照组高(P均<0.05);治疗后均较治疗前明显降低(P均<0.05)。治疗前后血浆S100β,NSE与带状疱疹患者病情严重程度呈正相关性(P均<0.001)。随访1个月PHN发生率为12%;发生PHN患者治疗前后病情评分、治疗后血浆S100β,NSE均较未发生者高(P均<0.05)。结论 HZ患者病情评分与其血浆S100β和NSE含量明显相关,其对HZ患者神经损伤病情评估和临床预后有一定参考价值。

Objective To investigate the correlation and clinical significance of severity score and plasma S100β and NSE levels in acute and recovery stages of herpes zoster（HZ）. Methods Fifty cases of hospitalized patients with HZ in the acute phase were enrolled as HZ group meanwhile samples from 20 cases of healthy blood donors were used as normal controls. The severity score was recorded using the HZ disease scoring criteria upon admission and at discharge. ELISA method was used to detect the concentration of S100β and NSE in plasma. To observe post-herpetic neuralgia （PHN）, HZ patients were followed up for 1 month after discharge. Results Treatment significantly lowered the severity score. Before and after treatment, the plasma levels of S100β and NSE were higher in the HZ group than in the normal controls （P 〈0. 05） ; After treatment, which were significantly lower than before （P 〈 0. 05 ）. Before and after treatment, the plasma levels of S100β and NSE positively correlated with the severity score of HZ （ P 〈 0. 001 ）. After 1 month of discharge, the incidence of PHN was 12% ;In comparison with non-PHN, patients with PHN exhibited higher severity score both before and after treatment（P 〈0. 05）, and higher plasma S100β and NSE post treatment （P 〈 0.05）. Conclusion The severity score significantly correlates with the plasma S100 and NSE in patients with HZ, which could serve as indicators to assess neurological damage and clinical prognosis in patients with HZ.